Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index; none of the 162 sources its claims cite is checked for support yet.

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Open access
Rees, Jon, Abrahams, Mark, Doble, Andrew, Cooper, Alison, the Prostatitis Expert Reference Group (PERG) · 2015 · BJU International

Abstract

Objectives: To improve awareness and recognition of chronic bacterial prostatitis ( CBP ) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) among non‐specialists and patients. To provide guidance to healthcare professionals treating patients with CBP and CP / CPPS , in both non‐specialist and specialist settings. To promote efficient referral of care between non‐specialists and specialists and the involvement of the multidisciplinary team ( MDT ). Patients and Methods: The guideline population were men with CBP or CP / CPPS (persistent or recurrent symptoms and no other urogenital pathology for ≥3 of the previous 6 months). Consensus recommendations for the guidelines were based on a search to identify literature on the diagnosis and management of CBP and CP / CPPS (published between 1999 and February 2014). A Delphi panel process was used where high‐quality, published evidence was lacking. Results: CBP and CP / CPPS can present with a wide range of clinical manifestations. The four main symptom domains are urogenital pain, lower urinary tract symptoms ( LUTS – voiding or storage symptoms), psychological issues and sexual dysfunction. Patients should be managed according to their individual symptom pattern. Options for first‐line treatment include antibiotics, α‐adrenergic antagonists (if voiding LUTS are present) and simple analgesics. Repeated use of antibiotics, such as quinolones, should be avoided if there is no obvious symptomatic benefit from infection control or cultures do not support an infectious cause. Early use of treatments targeting neuropathic pain and/or referral to specialist services should be considered for patients who do not respond to initial measures. An MDT approach (urologists, pain specialists, nurse specialists, specialist physiotherapists, general practitioners, cognitive behavioural therapists/psychologists, and sexual health specialists) is recommended. Patients should be fully informed about the possible underlying causes and treatment options, including an explanation of the chronic pain cycle. Conclusion: Chronic prostatitis can present with a wide variety of signs and symptoms. Identification of individual symptom patterns and a symptom‐based treatment approach are recommended. Further research is required to evaluate management options for CBP and CP / CPPS .

Overview

CoChat Summary

TL;DR

This consensus guideline from the Prostatitis Expert Reference Group provides symptom-based diagnosis and management recommendations for chronic bacterial prostatitis (CBP) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). It recommends individualized care across four symptom domains, cautious antibiotic use, early consideration of neuropathic pain treatment/referral, and a multidisciplinary approach.

Key findings

  • CBP and CP/CPPS should be managed by individual symptom pattern across four main domains: urogenital pain, lower urinary tract symptoms (LUTS), psychological issues, and sexual dysfunction; no single management pathway suits all patients.
  • Reported symptom burdens include perineal pain as the most prevalent pain localization (63%), irritable bowel syndrome in 22–31%, ≥1 LUTS in 39–68%, and in CP/CPPS cohort studies (n = 130–1,800) total/partial erectile dysfunction in 15–55% and overall self-reported sexual dysfunction in 46–92%.
  • First-line options include antibiotics, α-adrenergic antagonists if voiding LUTS are present, and simple analgesics; repeated quinolone use should be avoided if there is no obvious symptomatic benefit or cultures do not support infection, and early neuropathic pain treatment/referral plus multidisciplinary team care is recommended for non-responders.
  • In CBP, microbiological eradication rates were 40–77% for ciprofloxacin, 75% for levofloxacin, 80% for azithromycin, 77% for doxycycline, 80% for clarithromycin, and 62–77% for azithromycin + ciprofloxacin; most α-blocker RCTs showed positive results, but two larger placebo-controlled trials of tamsulosin (n = 196) and alfuzosin (n = 272) failed to show significant total NIH-CPSI differences.

Methods

  • Consensus guideline developed by the Prostatitis Expert Reference Group (PERG); guideline population were men with CBP or CP/CPPS, defined as persistent or recurrent symptoms and no other urogenital pathology for ≥3 of the previous 6 months.
  • Literature search on diagnosis and management of CBP and CP/CPPS published between 1999 and 7 February 2014, primarily Medline via PubMed, plus Cochrane Library and guideline groups including NICE and EAU; references graded using Oxford Centre for Evidence-based Medicine Levels of Evidence.
  • A web-based Delphi panel process was used where high-quality published evidence was lacking: three questionnaire rounds via Survey Monkey, circulated to 58 participants, with 35 (60%), 29 (50%), and 26 (45%) responding to rounds 1–3; consensus was defined as agreement of ≥70% of respondents, with PERG/technical input where consensus was not achieved.

Limitations

  • Paper-stated: there are limited published randomised controlled trials in CBP and CP/CPPS; the Delphi panel was used where high-quality evidence was lacking; many recommendations are Level 5; further research is required; there is no “gold standard” for definitive CP/CPPS diagnosis; evidence is scarce for pain pharmacotherapy, surgical interventions, and CBT/psychotherapy; many studies are small, lack placebo/control arms, or are heterogeneous.
  • Evident from the text: this is a consensus guideline rather than a systematic review or meta-analysis, and the Delphi panel had declining response rates (60% to 45%) with a ≥70% respondent consensus threshold, so several recommendations rest on expert opinion.
  • Evident from the text: some cited evidence is indirect or limited, such as the REDUCE dutasteride study not being primarily designed as a CP/CPPS treatment trial, and several physiotherapy, acupuncture, phytotherapy, and surgical findings coming from small pilot or proof-of-principle studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1111/bju.13101

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Treatment algorithm for the diagnosis and management of CBP and CP/CPPS. In patients describing typical neuropathic pain symptoms (e.g. ‘burning’, ‘shooting’ pain), or in any patient with persistent pain (>3 months), consider the possibility of neuropathic pain and treatment with appropriate anti‐neuropathic medication strategies.
Figure 1 Treatment algorithm for the diagnosis and management of CBP and CP/CPPS. In patients describing typical neuropathic pain symptoms (e.g. ‘burning’, ‘shooting’ pain), or in any patient with persistent pain (>3 months), consider the possibility of neuropathic pain and treatment with appropriate anti‐neuropathic medication strategies.CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 89 Not checked · 29 Own results and interpretations

64 more claims

Create a free account to see all 118 claims and to verify the 128 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 35
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 113 references

Research works printed but not linked: 2

  1. Nyberg LM, 1999, Textbook of Prostatitis, 28
  2. University of Oxford Centre for Evidence Based Medicine.OCEBM Levels of Evidence System. Available at:http://www.cebm.net/index.aspx?o=5653. Accessed June 2014

Cited by

Items 201–300 of 369

Metadata

Authors
Rees, J., Abrahams, M., Doble, A., Cooper, A., & the Prostatitis Expert Reference Group (PERG)
Affiliations
  • Backwell and Nailsea Medical Group Bristol UK
  • Addenbrooke's Hospital (GB)
  • Prostate Cancer UK (GB)
Corresponding author
Rees, Jon
Venue
BJU International
Publisher
Wiley
Published
2015-06-16
Volume
116
Issue
4
Pages
509-525
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W1997393900
Cited by
371
References
113
Citations by year
2026: 35 · 2025: 34 · 2024: 50 · 2023: 50 · 2022: 32 · 2021: 35 · 2020: 28 · 2019: 31 · 2018: 31 · 2017: 20 · 2016: 18 · 2015: 7
FWCI
21.78
Type
journal article
Language
en
Open access
Locations
  • British Journal of Urology (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
Funders
Prostate Cancer UK
Topics
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome, diagnosis, treatment, multidisciplinary team, lower urinary tract symptoms, urogenital pain, sexual dysfunction, neuropathic pain, alpha-blockers, antibiotics, quinolones, patient information, specialist referral
MeSH terms
Humans, Male, Prostatitis, Pelvic Pain, Consensus, Chronic Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.